Advertisement

Topics

Ablynx nv Company Profile

08:26 EST 15th December 2018 | BioPortfolio

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies™ therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody™ leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

Ablynx’s Nanobody™ technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.

Location

Technologiepark 4
Ghent
Zwijnaarde
9052
Belgium

Contact

Phone: 32 9 261.06.32
Fax: 32 9 261.06.28
Email: info@ablynx.com


News Articles [33 Associated News Articles listed on BioPortfolio]

Ablynx’s Success Story: The Past, Present and Future

Fintan Walton talks to Edwin Moses, CEO of Ablynx, about the success that the company has enjoyed since its inception, and his plans for it going forward. Edwin talks about the importance of location ...

Sanofi completes $3.9bn acquisition of Ablynx

Sanofi has completed the acquisition of biopharmaceutical company Ablynx for nearly $3.9bn following the expiry of the Squeeze-out procedure. The...Read More... The post Sanofi completes $3.9bn acquis...

The EMA Recommends the Approval of First Nanobody from Ablynx

Ablynx’s nanobody Cablivi is the first therapy for a rare blood disorder to receive a positive opinion from a committee of the European Medicines Agency (EMA).  Cablivi (caplacizumab) is a nan...

Sanofi closes purchase of Ablynx

Ablynx's outstanding shares, warrants and convertible bonds were fully acquired by Sanofi after the June 12 expiration of a s -More- 

Sanofi completes acquisition of Ablynx

Sanofi has now acquired all outstanding shares, warrants and convertible bonds of Ablynx following the expiration of the Squeeze-out procedure

Sanofi completes acquisition of Ablynx after squeeze-out period expires

Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx, following the expiration of the squeeze-out procedure.

CHMP recommends approval of Ablynx’s Cablivi to treat aTTP

Sanofi said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its subsidiary Ablynx’s Cablivi (caplacizumab) for the treatment of...

Nanobodies- combining the advantages of antibody drugs with the features of small-molecule drugs.

Ablynx is engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including i...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ablynx nv

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therap...

More Information about "Ablynx nv" on BioPortfolio

We have published hundreds of Ablynx nv news stories on BioPortfolio along with dozens of Ablynx nv Clinical Trials and PubMed Articles about Ablynx nv for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ablynx nv Companies in our database. You can also find out about relevant Ablynx nv Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record